VKTX - NASDAQ
Viking Therapeutics, Inc.
$29.88
+1.9%Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live Snapshotvktx
Total Other Income Expenses Net
Last Annual Value
33.70M
3-Year CAGR
183%
5-Year CAGR
60%
10-Year CAGR
17%
Viking Therapeutics, Inc. Competitors Analysis of Total Other Income Expenses Net
| Company | Total Other Income Expenses Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Viking Therapeutics, Inc. NASDAQ:VKTX | 33.70M | 31.2% | 117.5% | N/A | |
 Immunovant, Inc. NASDAQ:IMVT | 0.00 | N/A | N/A | N/A | |
 Akero Therapeutics, Inc. NASDAQ:AKRO | 33.36M | 16.5% | 214.2% | N/A | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 51.63M | 85.6% | 285.1% | 114.5% | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 34.09M | 15.1% | 63.5% | 28.6% | |
 Kymera Therapeutics, Inc. NASDAQ:KYMR | 37.78M | 26.7% | 160.8% | N/A | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 111.76M | 29.3% | N/A | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 5.94M | 35.3% | 57.2% | 14.1% | |
 NewAmsterdam Pharma Company N.V. NASDAQ:NAMS | 21.86M | 53.4% | N/A | N/A | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 22.93M | 94.9% | 142.9% | N/A |
Viking Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your VKTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.